Cartherics Pty Ltd

Cartherics is an Australian biotech company developing a range of allogeneic (off-the-shelf) immune cell products for the treatment of cancer. It has a technology platform based on gene-edited stem cells (induced pluripotent stem cells, or iPSCs) that can be expanded and differentiated into functional immune cells. The platform is underpinned by multiple patents and patent applications, most of which are owned by the company. Its lead product, CTH-401 is an iPSC-derived natural killer (NK) cell for the treatment of ovarian cancer (and potentially a range of other solid tumors). The company anticipates filing an IND for CTH-401 and entering clinical trials in 2025.
Cartherics is led by an internationally recognized team, with scientific and business expertise in stem cells, immunology, clinical development and oncology. It recently moved into its own purpose-built R&D facility in Notting Hill, Victoria, Australia where it houses its ~45 staff and has facilities.